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EVALUATING DISEASE CAUSATION IN
HUMANS EXPOSED TO TOXIC SUBSTANCES
Joseph V. Rodricks, Ph.D., D.A.B.T. *
INTRODUCTION
Individuals claiming they have been harmed by exposures to
chemical substances may seek compensation by bringing lawsuits
against those whose actions caused the exposures to occur.
Exposures may involve specific products, such as pharmaceuticals,
foods and many other consumer products, or industrial chemicals
used by workers in commercial operations of many types, or
chemicals emitted to the environment during their manufacture,
distribution, use, or disposal. Under our judicial system, those
making claims of harm, i.e. plaintiffs, are generally required to
offer evidence, through experts in medicine, epidemiology,
toxicology, and perhaps several other scientific disciplines, that a
causal relationship exists between the exposures they have
allegedly experienced and the specific type of medical injury or
disease they claim to have incurred. Defendants in such cases will
also seek out experts to evaluate and, if possible, counter the
evaluations of experts engaged by plaintiffs. Plaintiffs are
generally not faced with the scientifically impossible burden of
demonstrating causality with absolute proof; rather, the legal
standard is typically expressed as a need to demonstrate that
causality is demonstrable with a reasonable degree of scientific
certainty, or that it is more likely true than not true that the harm
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was caused by the exposure at issue.1
This paper is devoted to certain aspects of the problem of
evaluating disease causality in individuals when the putative cause
is a chemical substance. Not all of the elements of a causality
analysis will be discussed, must notably those concerning medical
diagnosis of a plaintiff’s condition and the often complex and
multifaceted problem of evaluating the nature, timing and
magnitude of the plaintiff’s exposure to the chemical(s) of interest.
Exposure analysis, which is a critical component of the evaluation
of causation, may be relatively straightforward in the case of
certain products, but may become exceedingly complex if it
involves reconstructing exposures arising from contaminated
environments, especially when there is evidence that the exposures
have been ongoing for long periods of time. Experts in exposure
evaluation come from many disciplines—chemistry, chemical and
environmental engineering, modeling of the movement of
chemicals through air or water or into the food supply, and
industrial hygiene—and even a partial discussion of the nature of
their work would significantly distract from the principal concerns
of this paper. For this presentation it is assumed that accurate
medical diagnoses can be achieved, and that reasonably accurate
estimates of plaintiff’s exposures can be derived.
The subjects of this paper pertain to the types of scientific
evidence that are useful for a determination of general causation
and specific causation, and of methods appropriate to evaluate that
evidence. The question of general causation is directed at an
evaluation of evidence that the chemical(s) at issue has been
established, through appropriate scientific studies, to cause the type
of injury or disease the plaintiff has developed. In the absence of
convincing evidence of general causation, it would not be possible
for a plaintiff, on the basis of the best available scientific
knowledge, to make a reasonably convincing case that his or her
specific disease was caused by exposure to the chemical at issue.
If, on the other hand, a reasonably convincing case could be made
1

FEDERAL JUDICIAL CENTER, REFERENCE MANUAL ON SCIENTIFIC
EVIDENCE 383, 547 n. 278, 547-48 n. 280, 548 n. 282 (2d ed. 2000) available at
http://www.fjc.gov/public/pdf.nsf/lookup/sciman00.pdf/$file/sciman00.pdf.
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that general causation has been established, the scientific
evaluation can move to the question of plaintiff-specific causation:
did the plaintiff incur sufficient exposure to the chemical at issue
to allow the conclusion that the plaintiff’s specific medical
condition was more likely than not caused by that exposure?2 For
example, an individual who was diagnosed with acute
myelogeneous leukemia and had experienced exposure to benzene
would have a compelling case for general causation. But if that
individual’s exposure were very low, it may not be possible for an
expert to show convincingly that specific causation can be
established. Benzene is not the only cause of this type of leukemia
and a demonstration that some undefined level of benzene
exposure had occurred is a far from adequate basis for establishing
specific causation.3
Even if general and specific causation have been established,
there may remain other factors in the plaintiff’s life that are even
likelier explanations for his or her condition; the subject of
“alternative causation” is also outside the scope of this paper, but
will be briefly discussed in a later section. General and specific
causation are thus the topics to be covered.
This paper shall begin in Part I with some general background
on chemical toxicity and the scientific methods used to identify the
toxic properties of specific chemicals. The use of toxicological
information by public health and regulatory authorities for
purposes of public health protection merits discussion because
there are certain parallels between the types of questions these
authorities pursue and those arising in a tort setting. In this regard,
the question of the utility of experimental data on toxicity,
typically derived from studies in laboratory animals, requires close
2

In some cases, a plaintiff may have been a member of a specific
population exposed to the chemical at issue and the subject of some type of
direct epidemiology study. Evaluating the likelihood that such a study could
provide evidence of both general and specific causation in the plaintiff requires
methods that are not discussed in this paper. This paper focuses on the far more
typical situation in which such studies have not been conducted.
3
In fact, because of its presence in gasoline, human exposure to some level
of benzene is virtually ubiquitous.
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scrutiny. Part II addresses how public health and regulatory
scientists evaluate the potentially adverse health consequences of
chemical exposures within a framework called risk assessment.
That same framework is useful for evaluating disease causation in
individuals, but we shall see that some of the types of scientific
evidence used commonly in the regulatory context may not be
appropriate for evaluating causation in individuals. Following that
discussion, in Part III, the evaluative methods used to understand
general and specific causation are outlined. This paper concludes
in Part IV with a discussion of the attendant limitations of general
and specific causation.
I. CHEMICAL TOXICITY AND SCIENTIFIC METHODS USED TO
IDENTIFY TOXIC PROPERTIES OF SPECIFIC CHEMICALS
Scientists undertaking toxicological risk assessments in the
regulatory setting commonly disagree on the interpretation of
specific study results, but they nevertheless work within a common
understanding of the types of scientific evidence appropriate for
such assessments. This common understanding has resulted from
half a century of scientific dialogue, much of it guided by many
expert reports on this topic issued by various arms of The National
Academies since the early 1980’s.4 No such history of scientific
discourse has informed the risk assessment process as it relates to
disease causation in individuals, and it is difficult to discern
anything remotely like a scientific consensus on how different
types of scientific evidence should be used in such assessments.
What is presented here might represent the thinking of most
4

The National Academies has issued hundreds of reports on specific issues
of chemical toxicity. For a recent example, see NAT’L RESEARCH COUNCIL,
HEALTH IMPLICATIONS OF PERCHLORATE INGESTION (2005), available at
http://www.nap.edu/books/030904894X/html/. For a broad view of approaches
to risk assessment, see COMM’N OF LIFE SCI., NAT’L RESEARCH COUNCIL, SCI.
AND JUDGMENT IN RISK ASSESSMENT (1994) [hereinafter SCIENCE AND
JUDGMENT], available at http://www.nap.edu/books/030904894X/html/;
COMM’N OF LIFE SCI., NAT’L RESEARCH COUNCIL, THE NAT’L RES. COUNCIL’S
COMMITTEE ON TOXICOLOGY: THE FIRST 50 YEARS (1997), available at
http://www.nap.edu/books/ 030904894X/html/.
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scientists, but no scientist writing on this topic would claim that it
represents a consensus, or that there are no alternative approaches
that might have utility. If an appropriate government sponsor could
be found, the subject of scientific evidence and disease causation
in individuals could surely benefit from a study by The National
Academies.
A. Chemical Toxicity
All chemical substances, whether of natural or synthetic origin,
can cause toxicity—some type of harm to the structure or
functioning of the body—under some conditions of exposure; thus,
as a technical matter, all chemicals can be said to be toxic.5 The
types of adverse health effects and the conditions of exposure
necessary to cause those effects vary widely among chemicals.6
The conditions under which we are exposed to most of the millions
of natural and synthetic chemicals that surround us are such that
their toxic properties are never expressed, but we recognize
perhaps hundreds of chemicals that do present some risk of toxicity
and that we are exposed to many more chemicals that have yet to
be investigated for their risk potential. Regulatory agencies, such
as the Environmental Protection Agency, the Occupational Safety
and Health Administration, and the Food and Drug Administration,
develop, for various administrative purposes, lists of hazardous
(toxic) substances.7 Chemicals so listed are usually those with
5

See PRINCIPLES AND METHODS OF TOXICOLOGY (A. Wallace Hayes ed.,
4th ed. 2001); JOHN TIMBRELL, INTRODUCTION TO TOXICOLOGY (3d ed. 2001).
The standard might be CASARETT AND DOULL’S TOXICOLOGY: THE BASIC
SCIENCE OF POISONS (Curtis Klaassen ed., 6th ed. 2001) [hereinafter CASARETT
AND DOULL’S]. The general background provided in this section is also
provided, in extended form, in JOSEPH RODRICKS, CALCULATED RISKS:
UNDERSTANDING THE TOXICITY AND HUMAN HEALTH RISKS OF CHEMICALS IN
OUR ENVIRONMENT (1992).
6
Dose, duration, timing, route of entry into the body, etc. David L. Eaton
& Curtis D. Klaassen, Principles of Toxicology, in CASARETT AND DOULL’S,
supra note 5, at 11, 13-14, 17-26.
7
Data on the toxic properties of most of the chemicals regulated by the
EPA can be found at http://www.epa.gov/iris/subst/index.html. OSHA’s listing
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well-recognized toxic properties and to which large numbers of
people are or could be exposed. It should be recognized that many
substances not listed as hazardous may well pose health risks under
some conditions and that not all listed substances will pose health
risks under all conditions of exposure.8 This topic will be
developed more fully in the later section on risk assessment.
Toxicity expresses itself in many different ways. Some
chemicals cause harm to the respiratory or nervous systems, while
others can harm the liver or the kidneys. Some chemicals may
cause harm to several different organs or systems of the body,
although the conditions of exposure necessary to cause harm in
different organs or systems often vary even for a specific chemical.
Many chemicals, which we label carcinogens, can cause malignant
tumors to appear in different cells of the body. There are chemicals
that can adversely affect immune or endocrine functions, or that
can interfere with reproductive processes. The developing embryo
or fetus is a target for some chemicals. In recent years much
attention is being devoted to the ways chemicals such as a lead and
methyl mercury, found in fish, can put children at risk of impaired
cognitive development or cause behavioral abnormalities. There is
an immense body of scientific literature concerning the adverse
effects of chemical exposures and the conditions under which they
occur, and it is now growing at a relatively rapid pace.9 Moreover,
of regulated workplace chemicals can be found at http://www.oshaslc.gov/SLTC/pel/index.html. The FDA has several centers that regulate
different categories of chemicals. See U.S. FOOD AND DRUG ADMIN., NAT’L
CTR. FOR TOXICOLOGY RESEARCH Home Page, http://www.fda.gov/nctr/
index.html. A comprehensive, integrated database on chemical toxicity can be
found at http://risk.lsd.ornl.gov/tox/tox_values.shtml. The Agency for Toxic
Substances and Disease Registry (ATSDR) provides comprehensive toxicity
reviews on many important chemicals. See ATSDR, TOXICOLOGICAL PROFILE
INFO. SHEET, http://www.atsdr.cdc.gov/toxpro2.html.
8
See Eaton & Klaassen, supra note 6, at 13-16. See also SCIENCE AND
JUDGMENT, supra note 4, at 25-42.
9
The National Toxicology Program is a multi-agency activity of the
Department of Health and Human Services and is both an important toxicology
and epidemiology research center and a source of information on the many
growing areas of research and testing of chemicals. See generally NATIONAL

RODRICKS MACROED.DOC

4/25/2006 11:00 PM

DISEASE CAUSATION AND TOXIC SUBSTANCES

45

many basic scientists have turned their attention to the difficult
scientific tasks of understanding the fine details of the chemical
and biological processes that take place after a chemical enters the
body and to the point at which its toxicity becomes detectable;
much progress is being made in understanding “toxic
mechanisms.”10
Although we are exposed to many thousands of chemicals,
including a large share of natural origin, present mostly as the nonnutritive constituents of food, it appears that we are not harmed by
most of these exposures.11 The absence of harm is probably
attributable to the fact that chemical toxicity does not express itself
under all conditions. Toxic responses are a function of the
magnitude of the dose12 and it is established with high certainty
that toxic responses do not appear until a so-called threshold dose
is exceeded;13 they increase in incidence, severity, or both, as the
dose increases above the threshold, but we are protected from harm
TOXICOLOGY PROGRAM, http://ntp-server.niehs.nih.gov.
10
See generally Harvey Clewell, Use of Mode of Action in Risk
Assessment: Past, Present, and Future, 42 REG. TOXICOLOGY AND
PHARMACOLOGY 3-14 (2005).
11
“Appears” is used here because it is extraordinarily difficult to acquire
knowledge about such potential risks. There is no way to document this
assertion because there has been no systematic study of most of the many
thousands of natural and synthetic chemicals to which all of us are exposed
daily, over our full lifetimes. But most human disease is attributable to the major
life-style factors—smoking, nutritional practices, alcohol abuse, infectious
diseases, lack of exercise—so it seems reasonable to conclude that we are able
to tolerate most chemical exposures without adverse consequence. See generally
WORLD HEALTH ORG., THE WORLD HEALTH REPORT: REDUCING RISKS,
PROMOTING HEALTHY LIFE 82 (2002) (summarizing the major sources of human
morbidity and mortality).
12
See Eaton & Klaassen, supra note 6, at 17-24 (explaining that dose refers
to the amount of chemical taken that actually enters the body usually per unit of
time as a result of exposure).
13
Id. at 19. See also INT’L PROGRAMME ON CHEM. SAFETY, PRINCIPLES
FOR THE ASSESSMENT OF RISKS TO HUMAN HEALTH FROM EXPOSURE TO
CHEMICALS, ENVTL. HEALTH CRITERIA 210, at 4.3.1, available at
http://www.inchem.org/documents/ehc/ehc/ehc210.htm
[hereinafter
INT’L
PROGRAMME].
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if the threshold dose is not exceeded. This “threshold hypothesis”
is well-documented, although it is not possible to claim the
hypothesis holds for every chemical or type of toxicity. In fact, as
shall be seen below, there is evidence it may be incorrect for
certain types of carcinogens.14 The issues of thresholds and doseresponse relationships are critical in the evaluation of specific
causation.15
B. Identifying Toxic Properties
It is, of course, unethical to test chemicals for toxicity in
humans. Pharmaceutical substances are delivered to human
subjects in controlled clinical trials, but only after there is
sufficient experimental animal data to provide high assurance that
the toxic properties associated with every drug will not be
expressed at the doses used in a trial. Adverse side effects may
occur during a trial, occasionally with a frequency or severity that
may require the trial to be halted. Clinical trials are conducted
under a set of internationally recognized ethical codes, which
recognize the important health benefits drugs confer.16 Such
controlled trials are clearly not appropriate for studying toxicity.
14

Compare Steve E. Hrudey & Daniel Krewski, Is There a Safe Level of
Exposure to a Carcinogen?, 29 ENVTL. SCI. & TECH. 370A (1995)
(summarizing the evidence on both sides of the “no-threshold” debate on
carcinogens), with Samuel M. Cohen, Human Carcinogenic Risk Evaluation: An
Alternative Approach to the Two-Year Rodent Bioassay, 80 TOXICOLOGICAL
SCI. 225 (2004) (providing several examples of threshold mechanisms for
carcinogens). See also Elaine M. Faustman & Gilbert S. Omenn, Risk
Assessment, in CASARETT AND DOULL’S, supra note 5, at 83, 92-99.
15
See sources cited supra note 5 (explaining that exposure refers to the
contact between an individual and the environmental medium in which a
chemical is present; dose refers to the amount of chemical that actually enters
the body usually per unit of time as a result of exposure; dose-response refers to
the quantitative relationship between dose and toxic response). See also INT’L
PROGRAMME, supra note 13, at 4.1 and 5.2 (respectively explaining doseresponse, exposure and dose).
16
WORLD MED. ASS’N, DECLARATION OF HELSINKI: ETHICAL PRINCIPLES
FOR MED. RESEARCH INVOLVING HUMAN SUBJECTS (1964) (amended 2004),
available at http://www.wma.net/e/policy/pdf/17c.pdf.
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Much can be learned about chemical toxicity by careful
observation of groups of individuals who experience common
exposures, usually incident to their occupations.17 Other discrete,
non-occupational cohorts may also be subject to such observational
studies.
Epidemiologists have developed several investigative methods
to conduct such studies and can design them in ways to build-in
some type of control group; however, none of these
epidemiological studies (cohort, case-control) are ever “controlled”
in the same way a laboratory experiment or clinical trial is
controlled.18 Only in well-controlled experiments can cause-effect
relationships be established with reliability. Individual
epidemiology studies are at best designed to identify whether a
statistical association exists between a chemical exposure and a
specific disease or toxic injury outcome – that is, to determine
whether one event, such as chemical exposure to a chemical,
occurs together with a second event, such as a specific disease or
toxic injury, more frequently than would be expected without such
17

These types of exposures are typically greater than those occurring in the
general population. Petroleum refinery workers are exposed to benzene in the
range of 0.5 to 1 ppm. The general population averages about 0.01 ppm. This
type of difference is typical for hundreds of industrial chemicals. There are
many reasons for these differences, but the major one is occupational situations
involving direct contact with and handling of chemicals. Emissions of these
same chemicals to the environment (air, water, food) results in significant
dilution. Alon Rosenthal, George M. Gray & John D. Graham, Legislating
Acceptable Cancer Risk from Exposure to Toxic Chemicals, 19 ECOL. L.Q. 269,
280 (1992) (discussing the need to extrapolate from high dose occupational
exposures to low levels of environmental exposure).
18
Clinical trials are inherently not as well-controlled as experiments
involving animals, where environments, diet, and genetic characteristics in test
and control groups are virtually identical except for the presence of the chemical
under test. Brian L. Strom, Study Designs Available for Pharmacoepidemiology
Studies, in PHARMACOEPIDEMIOLOGY 17, 17-29 (Brian L. Strom ed., 3d ed.
2000). See also LEON GORDIS, EPIDEMIOLOGY chs. 7, 12 (2d ed. 2000) (on
randomized trials and comparing cohort and case-controlled studies); Nelson H.
Wilson et al., Short-Term, Subchronic, and Chronic Toxicology Studies, in
PRINCIPLES AND METHODS OF TOXICOLOGY, supra note 5, at 917, 932, 936-38
(discussing well-controlled animal studies).
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chemical exposure. Other factors that may bias or confound any
observed association also need to be identified and, if possible,
eliminated as alternative explanations for the association.19
Although epidemiological studies are highly relevant to
identifying the toxic properties of chemicals that are of concern for
our species, no single study is sufficient to establish causation.
Epidemiologists await a body of evidence from several studies,
ideally involving different study methods, investigators, and
population groups. Consistency among study outcomes and clear
evidence that risk increases with increasing exposure (dose),
strong statistical associations, and supporting experimental data,
are considered the necessary hallmarks of true causality;
nonetheless, causality can never be determined with complete
certainty.20 Expert groups, such as those convened by bodies such
as the International Agency for Research on Cancer (IARC), a unit
of the World Health Organization, or the federal National
Toxicology Program, periodically review evidence and typically
assign weights to it.21 The IARC, for example, describes the
19

Michael D. Green et al., Reference Guide on Epidemiology, in
REFERENCE MANUAL ON SCIENTIFIC EVIDENCE, supra note 1, at 333.
20
GORDIS, supra note 18, at 184-218 (providing a thorough discussion of
approaches to evaluating causality). See also sources cited infra note 21
(referencing reports on causality of carcinogens from the International Agency
for Research on Cancer, Environmental Protection Agency, and U.S.
Department of Health and Human Services).
21
The International Agency for Research on Cancer (IARC), a division of
the World Health Organization (WHO), issues expert reports on causes of
cancer. Reports on occupational and other sources of carcinogens each contain
descriptions of how epidemiological and experimental evidence is evaluated in
each instance to reach conclusions regarding causation. See IARC,
http://www.iarc.fr (last visited Oct. 27, 2005). See also RISK ASSESSMENT
FORUM, ENVTL. PROTECTION AGENCY, GUIDELINES FOR CARCINOGEN RISK
ASSESSMENT (1999) [hereinafter RISK ASSESSMENT FORUM], available at
http://oaspub.epa.gov/eims/eimscomm.getfile?p_download_id=439797
(providing EPA’s framework for assessing possible cancer risks); U.S. DEP’T OF
HEALTH & HUMAN SERV., NAT’L TOXICOLOGY PROGRAM, REPORT ON
CARCINOGENS (11th ed. 2005), available at http://ntp-server.niehs.nih.gov/
index.cfm?objectid=32BA9724-F1F6-975E-7FCE50709 CB4C932 (discussing
agents, substances, mixtures, and exposure circumstances that may pose a
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evidence on specific substances, or sometimes mixtures of
chemicals or even certain occupational settings in which the
specific causative chemical(s) has not been identified, as sufficient
when causal criteria are judged to have been met by the agency’s
expert panels.22 The IARC’s expert panels also describe evidence
on other substances as sufficient to establish an association but
insufficient to establish causation, or as only insufficient.23 At the
present time, the IARC lists 95 substances, mixtures, or
occupations as causally related to cancer, based on epidemiological
data.24 It can be said that any substance so listed qualifies as a
hazard to human health by virtue of their carcinogenicity).
22
See, e.g., 77 IARC, WHO, MONOGRAPHS ON THE EVALUATION OF
CARCINOGENIC RISKS TO HUMANS: SOME INDUSTRIAL CHEMICALS (2000)
[hereinafter SOME INDUSTRIAL CHEMICALS], available at http:wwwcie.iarc.fr/htdocs/indexes/vol77index.html (describing studies of sixteen specific
chemicals where there was insufficient evidence to establish causation in
humans). But see 62 IARC, WHO, MONOGRAPHS ON THE EVALUATION OF
CARCINOGENIC RISKS TO HUMANS: WOOD DUST FORMALDEHYDE 35 (1998),
available
at
http://www-cie.iarc.fr/htdocs/monographs/vol62/wood.html
(finding sufficient evidence of cancer causation in humans in case of wood dust,
based on a large body of case-control and cohort studies).
23
IARC, WHO, MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC
RISKS TO HUMANS: PREAMBLE (1999), available at http://www-cie.iarc.fr/
monoeval/eval.html (listing categories used to classify the degree of evidence
related to carcinogenicity in specific organs or tissues). Evidence regarding
specific substances may fall into these categories if some, but not all, of the
criteria described in the opening sentences of this paragraph are met. Expert
committees provide descriptions of the available evidence and why it may fail to
meet criteria for causation. See also SOME INDUSTRIAL CHEMICALS, supra note
22 (listing IARC descriptions of the evidence for any of the 16 chemicals
evaluated and reasons why causation criteria were not met).
24
In all, IARC expert panels have evaluated 900 individual substances,
chemical mixtures, and occupational exposure situations. IARC, WHO, LISTS OF
IARC EVALUATIONS (2004), available at http://www-cie.iarc.fr/monoeval/
grlist.html. The evidence that each substance, mixture, and occupational
exposure causes cancer is rated on a scale of 1-4; 1 is for agents that definitely
cause cancer and 2A is for those that probably cause cancer. Id. Categories 1 and
2A may be sufficient to establish general causation as a matter of law. See
REFERENCE MANUAL ON SCIENTIFIC EVIDENCE, supra note 1 & accompanying
text. Roughly 20 percent of evaluated substances, mixtures, and occupational
exposures fall into category 1 or 2A. IARC, WHO, OVERALL EVALUATIONS OF
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general cause of the specific type(s) of cancer for which it is listed,
although experts can be found who will have reasons to question
the IARC’s listings. In any event, there is no stronger evidence for
general causation of chemical toxicity than that obtained from a
body of epidemiological evidence meeting causation criteria.25
Exceptions to this rule may apply in the case of pharmaceutical or
other medical products, because controlled clinical trials are more
readily useful for establishing causation (or its absence) than are
epidemiological studies.26
Epidemiological studies cannot be conducted until after
chemical products are introduced into commerce and for some
diseases, such as cancers with latency periods of many years or
decades, much time must pass before results can be collected and
evaluated. For these and other reasons, toxicologists have
developed and continue to improve various methods for collecting
toxicity data in laboratory animals. Toxicology studies in animals
began to be used in the 1930’s and for a time focused on relatively

CARCINOGENICITY TO HUMANS (2004), http://www-cie.iarc.fr/monoeval/
crthall.html.
25
Differential diagnoses are frequently used by examining physicians to
identify the cause of a medical condition in individual patients. In most cases,
the physician relies upon established knowledge regarding the various causes of
specific conditions. In some cases, a physician may think he or she has
identified a new (previously unreported) cause for a disease or injury and may
seek publication in medical journals of the findings. Such “case reports,”
especially if a series of similar reports appears over time, can be of high value in
generating hypotheses about causal relations. Such hypotheses can then be
studied epidemiologically, but establishing causal relationships based only on
such reports is highly problematic because in the absence of controls, it is nearly
impossible to determine whether the condition would also have occurred in the
individual patient in the absence of exposure to the suspect chemical. See
GORDIS, supra note 18 (describing why such case reports are of highly limited
utility in establishing causation); Judith K. Jones, Determining Causation from
Case Reports, in PHARMACOEPIDEMIOLOGY, supra note 18, at 525-38
(discussing the limitations and the potential value of such reports). See also
STROM, supra note 18, at 22.
26
See STROM, supra note 18, at 26-27 (“Randomized clinical trials are ‘the
gold standard’ by which other designs must be judged.”).
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intense exposures of limited duration.27 Nowadays, studies
typically involve several species, extend over the animals’
lifetimes, and involve an examination of reproductive and
developmental effects. Every manifestation of a chemical’s
toxicity can be uncovered using animals through detailed tissue
pathology (this is not even remotely possible in human studies). As
noted earlier, because such studies are strictly controlled, they can
be used to identify cause-effect relationships with greater
reliability.
C. Utility of Animal Data
Rats, mice, dogs, and pigs are commonly used in toxicology
experiments and, although there is extensive work underway to
identify test systems that will not require the use of whole animals,
it is likely such experiments will continue to be carried out,
because of the intense interest in the United States and in the
European Union (the EU) to acquire more complete toxicology
data on ever greater numbers of chemicals.28 The primary uses of
such data are to identify the toxic properties of chemicals, the
threshold doses for toxicity, and, through the use of a method
termed ‘risk assessment,’ exposure levels (doses) that will not pose
toxic risks to human populations.
While regulatory agencies prefer to use epidemiological
evidence to identify protective levels for human populations, they
will not hesitate to use animal toxicology data when human data
are limited or altogether lacking.29 There is substantial scientific
27

Joseph F. Borzelleca, The Art, the Science, and the Seduction of
Toxicology: An Evolutionary Development, in PRINCIPLES AND METHODS OF
TOXICOLOGY, supra note 5, at 1-22.
28
The regulators of the European Union (the EU) are in the process of
developing a Registration, Evaluation, and Assessment of Chemicals program
(REACH). At present, it targets thousands of chemicals for testing. Whether
this ambitious goal is retained in the program’s final form is unknown. See
generally REACH, at http://europa.eu.int/comm/environment/chemicals/
reach.htm.
29
See ENVTL. PROTECTION AGENCY [hereinafter EPA], INTEGRATED RISK
INFORMATION SYSTEM [hereinafter IRIS], available at http://www.epa.gov/
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basis for this regulatory policy.30
First, factors that influence toxicity are generally similar across
mammalian species, as are cells, cellular components, and
extracellular environments.31 Thus, biological factors that
influence a chemical’s behavior in the body and its interaction with
the specific sites where it causes damage are generally similar
across all mammalian species. These basic biological similarities
suggest that chemicals that produce specific forms of toxicity in
animals will also do so in humans, given a sufficient dose;
however, similar does not equate to identical.32
While there appears to be a concordance between the types of
toxic responses seen in animals and that observed in humans for
those cases in which both human and animal data are available,
often for unexplained reasons the specific manifestations of
toxicity (e.g., type of cancer) differ across species.33 Thus, while
iris/subst/index.html. The EPA has evaluated the toxic properties of hundreds of
chemicals and derived toxicity risk factors based on either human or animal
evidence. Animal evidence is the primary source for these risk factors, because
human evidence is either lacking or is inadequate. Good examples of chemicals
listed in the IRIS database that are regulated based on animal data are
acrylamide, acrylonitrile, and carbon disulfide. See EPA, OFFICE OF THE SCI.
ADVISOR, RISK ASSESSMENT PRINCIPLES & PRACTICES 76-77 (2004) [hereinafter
EPA, RISK ASSESSMENT PRINCIPLES & PRACTICES], available at
http://www.epa.gov/osainter/pdfs/ratf-final.pdf (providing examples of four
substances for which some human data on toxicity were available but were not
used for IRIS toxicity evaluations. In each case, the agency used animal data to
derive toxicity factors).
30
The clearest exposition of the basis for this regulatory policy can be
found in a volume published by a committee of the National Research Council.
See generally, COMM. ON THE INSTITUTIONAL MEANS FOR ASSESSMENT OF
RISKS TO PUB. HEALTH, NAT’L RESEARCH COUNCIL, RISK ASSESSMENT IN THE
FED. GOV’T: MANAGING THE PROCESS (1983) [hereinafter RISK ASSESSMENT IN
THE FEDERAL GOVERNMENT] (establishing the risk assessment framework that is
used by regulatory and public health institutions throughout the world).
31
I.e., Anatomy, physiology, and biochemical processes. See RISK
ASSESSMENT PRINCIPLES & PRACTICES, supra note 29, at § 4.
32
See RISK ASSESSMENT IN THE FEDERAL GOVERNMENT, supra note 30.
33
Harry Olson et al., Concordance of the Toxicity of Pharmaceuticals in
Humans and Animals, 32 REGULATORY TOXICOLOGY AND PHARMACOLOGY, 56,
56-67 (2000) (discussing a careful study on this issue and also providing
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regulators may be on solid ground to conclude that an animal
carcinogen may be a human carcinogen, they would be on much
shakier ground if they were to conclude that the specific type of
cancer (or other toxicity) that occurs in animals is also likely to
occur in sufficiently exposed humans.34
For regulatory purposesthat is, for purposes of developing
standards to limit exposures to ensure protection of human
populationsit is not essential to know which specific type of
cancer or other disease is caused by a chemical. For public health
protection, that particular type of scientific uncertainty is not
important, or so the regulators have traditionally held.35
Another factor limiting the use of animal data for drawing
strong inferences about humans concerns the doses necessary to
cause adverse effects. Here, animal-human differences seem to be
significant, and the magnitudes of those differences are generally
unpredictable. For example, even if a chemical established as
causing liver injury in rodents is assumed to be a liver toxicant in
humans, identifying the human dose necessary to cause that
toxicity is not possible without imposing incompletely tested
assumptions.
Thus, while animal data are routinely used for public health
protection, they are of limited utility for establishing general
causation in humans. They may be used to buttress findings from
human studies, but when no human data are available, it would
seem to stretch scientific understanding beyond its limits to
conclude that specific health effects found in animals will with a
reasonable degree of scientific certainty be expected to occur in
examples). See also RODRICKS, supra note 5, at 137 tbl. 7 (citing animal-human
differences in cancer-types related to the same chemical).
34
See 2 INSTITUTE OF MEDICINE OF THE NAT’L ACADEMIES, BOARD ON
HEALTH PROMOTION & DISEASE PREVENTION, GULF WAR AND HEALTH:
INSECTICIDES AND SOLVENTS 98-349 (2003) (providing an extended discussion
on this issue and evaluating the general disease causation for chemical
substances to which U.S. military personnel may have been exposed during the
Gulf War).
35
See RISK ASSESSMENT FORUM, supra note 21. The EPA recognizes that
animal cancer data may not predict specific cancer types in humans, but
frequently uses such data for human cancer risk assessment. Id. § 2.2.2.1.
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sufficiently exposed humans; and identifying sufficient exposure
from the animal data is even more problematic.36
II. REGULATORY RISK ASSESSMENTS
“Risk assessment” is a framework within which data regarding
the adverse health effects caused by chemicals derived from
epidemiological and experimental studies, and information
regarding the conditions under which human populations are or
could be exposed to those chemicals, are integrated to yield a
description, usually quantitative in nature, of the likelihood that
those adverse effects will occur in the exposed populations.37 That
likelihood of adverse effects occurring in the exposed populations
is called a risk.38 Risk assessment serves to bridge the gap between
research and the needs of so-called risk managers; the latter are
typically regulatory and public health decision-makers. Research
findings and other forms of data arise from diverse sources, have
varying degrees of utility and quality, and are not infrequently
contradictory; risk assessors have the difficult task of making sense
of such data and using the results to present risk managers with as
coherent a description of risk as the underlying science allows.
Risk assessments are typically directed at an existing exposure
situation, such as the risks incurred by populations residing in the
vicinity of a manufacturing or hazardous waste facility, or at the
exposure situation expected if certain regulatory actions are
taken.39 Those actions are usually taken if the existing risks are
judged excessive; risk assessors’ goal is to reduce risks to
acceptably low levels, the technical definition of safe levels.40
36
37

See REFERENCE MANUAL ON SCIENTIFIC EVIDENCE, supra note 1.
See RISK ASSESSMENT IN THE FEDERAL GOVERNMENT, supra note 30, at

18.
38

Id.
EPA, RISK ASSESSMENT PRINCIPLES & PRACTICE, supra note 29, at 99112 (providing a thorough description of how the agency approaches all the
human exposure circumstances associated with a typical (and complex)
hazardous waste site, as the focus of its risk assessment process).
40
“Safe” is often taken to mean the complete absence of a risk. As a
39
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Often, risk assessors evaluate the epidemiology, toxicology, and
dose-response information for purposes of establishing a safe
exposure level for a specific chemical.41 Those safe levels are then
used to establish standards for the chemical that apply to specific
environmental mediaallowable limits on the concentrations of
the chemical in water, air, food, or soil, or in workplace
environments. Measured concentrations of chemicals in these
media can be compared with the standards to determine whether a
risk exists.
The foundations for current approaches to risk assessment were
set forth in a study produced in 1983 by the National Academy of
Sciences.42 The study authors noted that, given the current state of
scientific understanding, which has improved in the past 20 years
but has not overcome the basic problems in risk assessment, and
also given the compelling need to conduct risk assessments for
public health protection, regulators would be required to invoke
certain assumptions in the conduct of risk assessments.43 These
assumptions address the limits of our knowledge and may not have
firm scientific support, but risk assessments cannot be completed
without them.
In the context of regulatory risk assessment three such issues
stand out: 1) the need to extrapolate from epidemiological and
technical matter such situations—which require proof of a negative condition—
cannot be demonstrated to exist. Completely safe conditions may actually exist,
but there is no scientifically rigorous method for identifying them. RODRICKS,
supra note 5, at 204-11 (providing a discussion of the relationship between
safety and risk). The toxicity risk factors (“Reference Doses”) derived and
presented by the EPA in its IRIS database are used as maximum “safe” exposure
levels for chemicals. See IRIS, supra note 29. The Reference Dose is, however,
not characterized by the agency as safe, but rather as a dose at which the
probability of an adverse toxic response is negligibly small. See Barbara D.
Beck et al., The Use of Toxicology in the Regulatory Process, in PRINCIPLES
AND METHODS OF TOXICOLOGY, supra note 5, at 23, 47.
41
Beck et al., supra note 40, at 23. The entire chapter is devoted to the
methods used to establish the safe (negligible risk) doses set forth in EPA’s IRIS
database. Nearly identical methods are used by other agencies. See also sources
cited supra note 13.
42
RISK ASSESSMENT IN THE FEDERAL GOVERNMENT, supra note 30.
43
Id. at 51-85. See also id. at 7 (Recommendation B).
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experimental results obtained at doses substantially greater than
those incurred by populations that are the typical subjects of risk
assessments; 2) the need to extrapolate from experimental results
to human beings; and 3) the need to deal with the known potential
for variability in response to chemical exposures among a large,
diverse human population. Scientific knowledge in these areas is
limited. Other such limitations exist regarding the nature and
extent of human exposures. Regulators have responded to the
National Academy of Sciences study by describing the usual
default assumptions to be used, while noting that in specific cases
scientific knowledge may exist to permit departures from those
assumptions.44 Risk assessment is, thus, not a scientific activity in
the usual sense; moreover, in many cases, testing the results of a
risk assessment by additional epidemiological investigations is
beyond current scientific capabilities.45 In the absence of any
attempt to assess risks, it is not possible to have an understanding
of whether public health is adequately protected, or whether new
products can be safely introduced into commerce.
The approach to chemical risk assessment used by regulatory
authorities is designed to evaluate risks to what might be called
“generic” individuals.46 It is recognized that responses to chemical
44

See RISK ASSESSMENT FORUM, supra note 21.
Regulatory and public health policies attempt to ensure that risks are
controlled at levels substantially below those that can be identified using the best
available epidemiology tools. Arhtur C. Upton, Perspectives on Individual and
Community Risks, in ENVIRONMENTAL TOXICANTS 905-11 (Morton Lippman
ed., 2nd ed. 2000). Public health policies are limited to detecting relatively large
risks. Some scientists argue that precious resources are wasted in regulating
“non-detectable risks” (i.e., those that are estimated using the regulatory risk
assessment approach), but regulatory and public health officials have generally
interpreted our laws as requiring the cautious approach to public health
protection. See Gary Taubes & Charles Mann, Epidemiology Faces its Limits,
269 SCIENCE 164, 164-69 (1995).
46
By use of the term generic, I mean hypothetical individuals within
populations that are the subjects of risk assessments that are assumed to be
equally sensitive to the hazardous effects of a chemical. “Generic” is my shorthand. See SCIENCE AND JUDGMENT, supra note 4, ch. 10 (discussing the issue of
variability at length). Inspection of the process used by EPA (IRIS data base)
reveals how the risk assessment process is designed to focus on the high-risk
45
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exposures are variable within populations, and regulators target
those generic individuals who are at the high end of sensitivity. If
standards are developed to protect those individuals, then all others
in the population, who are less sensitive, can be assumed to be
protected. Moreover, regulators estimate population exposures by
making assumptions that target those similarly generic individuals
at the high end of the range of population exposures.47
It is not possible to determine, except in unusual
circumstances, which actual individuals in a population are at the
high end of sensitivity and also at the high end of exposure. In this
sense it can be said that regulatory risk assessments apply to
generic, as opposed to actual individuals. This fact alone limits
significantly the applicability of regulatory risk assessments and
the various standards derived from them to the evaluation of
general and specific causation in actual individuals. Further, for at
least those regulatory risk assessments and standards that are based
primarily on experimental animal data, the relevance to individual
causation analysis is highly dubious.48
A final point regarding regulatory risk assessments is that the
so-called safe levels are derived from the epidemiological or
experimental toxicity data by the use of assumptions49 that have
the effect of placing those levels at a very small fraction of the
observed threshold levels.50 The reasons for this effect are
(most sensitive) responders in the population. See IRIS, supra note 29.
47
See SCIENCE AND JUDGMENT, supra note 4, 43-55 (in particular, note the
section entitled Maximally Exposed Individual at 46).
48
See discussion supra Part I.C.
49
Sometimes expressed in the form of certain mathematical models. It is
common, for example, to use what is called a linear, no-threshold model to
estimate low dose cancer risks, based on data obtained at high doses. See
Faustman & Omenn, supra note 14, at 75-88 (describing such a model); Beck et
al., supra note 40.
50
Regulators assume, in the absence of evidence to the contrary, that
carcinogenic chemicals act through mechanisms that disobey the general
“threshold” rule for toxicity. This does not translate to the sometimes expressed
view that any level of carcinogen exposure can cause cancer. See sources cited
supra note 14. See also Upton, supra note 45 (describing regulated risk levels).
Instead, it means only that any exposures to carcinogens will increase cancer
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complex, and will not be described here, but they are related to
general knowledge regarding the behavior of chemicals when they
are present at toxic levels, and the lack of specific knowledge
pertaining to the magnitude of human variability, animal-to-human
and high-to-low dose extrapolation, and many other aspects of a
risk assessment. Because of this and because the regulatory
standards are designed to protect the generic, highest risk
individuals, it is likely that actual individuals in a population
exposed at levels less than those standards are not at risk.
Exposures at levels in excess of regulatory standards will not
necessarily lead to toxic injury or disease; knowledge that such
exposures have occurred is, by itself, completely inadequate to
establish disease causation in individuals. This is not an expression
of lack of concern for situations in which regulatory standards are
exceeded. It is rather a statement regarding the lack of utility of
this kind of information for assessing injury causation in actual
individuals.
III. GENERAL AND SPECIFIC CAUSATION IN ACTUAL INDIVIDUALS
There are models of evaluation, similar conceptually but not in
actual execution to the regulatory risk assessment model, that are
useful for evaluating general and specific causation in actual
individuals. Assuming that a plaintiff has been properly diagnosed
as having a specific disease or injury, and assuming that the legal
standard for establishing causation is the more likely than not
criterion, a court may proceed through the evaluation using the
following lines of inquiry:
i. To what chemical was the plaintiff exposed?
ii. Is there sufficient evidence in the scientific literature to
support a causal relationship between exposure to the
risk and that the magnitude of the risk increases with increasing exposures.
Regulators do not become concerned until lifetime (calculated) cancer risks
reach probabilities of one-in-one million or greater. The no-threshold approach
is not based on highly certain scientific knowledge, and there may be many
exceptions to it. See RISK ASSESSMENT FORUM, supra note 21.
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chemical and the specific type of injury or disease the
plaintiff has incurred?
If the answer to (ii), the general causation question, is no (using
the scientific criteria for judging general causation from
epidemiological studies, described above), then the inquiry ends. If
the answer is to (ii) is yes, then the inquiry continues. It might also
continue if the answer were “strong associations established, if not
causation, and supporting evidence from experimental studies,”
because additional evaluation might assist in dealing with such an
ambiguity. Thus, the next inquiry:
iii. What is the likelihood that someone having the
plaintiff’s characteristics (age, sex, race, smoking habits,
alcohol consumption rates, etc.) would have the specific
injury or disease in the absence of exposure to the suspect
chemical?
Very few diseases or injuries have unique causes; most have
multiple causes including, in our hypothetical case, the suspect
chemical. Even if alternative causes are unknown, it may be
understood that many individuals acquire the condition in the
absence of exposure to the suspect chemical.51 Health statistics
may be available to help answer inquiry (iii) with a reliable degree
of quantification, especially in the case of cancer. Plaintiff’s
condition may be vary rare, in which the likelihood of
demonstrating specific causation (inquiry (iv), infra) increases; it
becomes difficult to establish specific causation if the plaintiff’s
condition is a very common one. Thus, this next inquiry:
iv. Did the plaintiff incur exposures to the suspect chemical
of sufficient magnitude and duration to make it more likely
true than not that the chemical, and not some other factor,
was the cause of the plaintiff’s medical condition?

51

Very few chemicals are known to be both necessary and sufficient causes
of human disease. For example, although benzene is said by IARC to be a cause
of certain types of human leukemias, it is by no means the only such cause and,
in fact, most cases occur in the absence of benzene exposure. This same pattern
exists for virtually all chemical carcinogens. See sources cited supra note 19 and
infra note 54.
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In the absence of some measure of exposure conditions,52 it is
difficult, if not impossible, to establish specific causation. This
conclusion stems from the fact that the risk of toxicity changes
with dose and does not become even minimally significant until
the threshold for toxicity is exceeded for sufficient periods of
time.53
It is not scientifically possible to determine, for a specific
individual, what the threshold value is; but examination of the
dose-response data from the epidemiological studies used to
demonstrate general causation should reveal the magnitude of
exposure necessary to increase risk above background levels.54
Some have addressed the more likely true than not criterion by
identifying, from the dose-response data, the so-called risk
doubling dose: the dose required to double the background risk.55
Thus, for example, if the specific plaintiff’s risk of developing his
or her specific disease in the absence of exposure to the suspect
chemical is one-in-one thousand, examination of the dose-response
data from the epidemiological data can reveal the magnitude of the
dose necessary to increase risk by a factor of one-in-one thousand.
If the exposure experts can demonstrate that the plaintiff incurred
52

I.e., dose, duration, timing relative to injury, route of entry into the body,
etc. See discussion supra Part I.A.
53
See supra Part I.A. See also Philip S. Guzelian et al., Evidence-Based
Toxicology: A Comprehensive Framework for Causation, 24 HUMAN AND
EXPERIMENTAL TOXICOLOGY 161, 161-201 (2005). This paper contains an
excellent (though complex) discussion of the general problem of causation, as
well as specific guidance regarding toxicological questions.
54
Dose-response relationships identified in epidemiology studies provide
information regarding the extent of disease risk increase that is associated with a
given increment in exposure. Epidemiologists collect information on exposures
incurred by the populations under study and typically distinguish subpopulations
having exposures of different magnitudes and duration. Evidence that disease
risk increases as exposure increases is used as supportive of a causal
relationship. See GORDIS, supra note 18. See also sources cited supra note 21.
55
Phillip Cole, Causality in Epidemiology, Health Policy, and Law, 27
ENVTL. LAW REP. 10279 (1997). In the determination of general causation,
epidemiologists often use the risk-doubling criterion as a rule-of-thumb in
establishing reliable statistical associations. This use of the criterion is different
from that described here for examining specific causation.
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exposures leading to a dose of at least that magnitude, then it can
be concluded that exposure to the suspect chemical increased
plaintiff’s disease risk to a level of at least two-in-one thousand
(1/500). Thus, it may be concluded that, since the plaintiff actually
has the disease, then the risk has been realized, and it is more
likely that it was caused by the chemical than by whatever other
factors cause the condition. This conclusion derives from the fact
that, since the plaintiff’s risk was greater than two-in-one
thousand, and that factors other than the suspect chemical
contributed less than half of the plaintiff’s total risk (no more than
one-in-one thousand), then there was a greater than 50% chance
his or her condition was due to the chemical exposure and not
other factors. If the exposure incurred by the plaintiff does not
create a risk doubling dose, then under the criteria used here, it
cannot be claimed specific causation has been demonstrated.56
This sketch of how the analysis of specific causation may
proceed is meant to describe the type of analysis necessarythe
scientific method to be usedand is not intended to describe a
strict set of inflexible criteria (such as, for example, a strict riskdoubling standard). A degree of scientific judgment is necessarily
involved, especially since the data required to conduct a careful,
quantitative evaluation of the plaintiff’s exposures and
epidemiological dose-response relationships are almost never
without uncertainty. Alternative approaches, including what
epidemiologists call attributable risk analysis (similar conceptually
to what has been described but somewhat different in form) may
also be applied. Whatever is undertaken in the analysis of specific
causation, it should be clear that the mere fact that the plaintiff can
demonstrate some exposure to a substance for which general
causation has been established is hardly sufficient, even if that
exposure exceeds some applicable regulatory standard.
There is a role for additional analysis in certain cases, because
it is possible that alternative and even more likely causes of a
specific plaintiff’s harm can still be found, even if criteria for
specific causation seem to be satisfied. This enters the domain of
56

Id.
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what is sometimes called differential medical diagnosis, which I
leave to others, except to say such diagnoses, whether they are
intended to demonstrate causation or its lack, are by themselves
inadequate evaluative tools.57
IV. LIMITS IN PROVING CAUSATION
The framework outlined for evaluating general and specific
causation consists of elements that parallel those contained in the
risk assessment framework used by regulatory agencies. It consists
of an examination of the toxic effects produced by a chemical, the
conditions of exposure necessary to produce those effects, the
relationships between dose and effect, and the conditions under
which humans (populations or individuals) have been or may
become exposed. Some important differences between the types of
scientific evidence used to conduct risk assessments in the tort and
regulatory or public health contexts also exist, and the results from
regulatory risk assessments will, in most cases, be of highly limited
utility in the examination of individual disease causation.
Although the general process described here for undertaking an
evaluation of general and specific causation may have broad
acceptance, it seems clear that nothing approaching the uniformity
of scientific approaches that can be discerned in the regulatory
context exists in connection with the evaluation of individual
exposures and responses. The relative weights given to different
types of scientific information may vary greatly among experts,
and there appears to have been little substantive discussion of the
problem of individual disease causation in the scientific, as against
the legal, literature.58
One issue that transcends the scientific literature concerns the
question of the potentially excessive burden placed upon plaintiffs
if they are required to show with a reasonable degree of scientific
rigor that their injuries or diseases have been caused by chemical
exposures. Although legal standards would seem to call for such
57

See sources cited supra note 26.
A recent publication by Philip Guzelian and associates perhaps signals a
break in this trend. Guzelian, supra note 53, at 161-201.
58
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rigor, the data requirements necessary to apply appropriate
scientific methods can sometimes be substantial, difficult, and
costly to develop. Establishing general causality for any chemical
requires extensive scientific investigation. Plaintiffs can, of course,
incorporate existing scientific knowledge regarding those
chemicals for which general causal relations with certain injuries
or diseases have been established, but they are still required to
develop evidence to support specific causation. For substances for
which general causal relations have not been substantiated, it is
difficult to imagine circumstances in which plaintiffs could
develop such evidence. This conclusion must, however, be
qualified by noting that it is premised on the view that establishing
general causation requires the types of evidence described in this
paper; clearly scientists may disagree on this matter. It is also
likely that, in considering the types and strengths of different
sources of scientific evidence necessary to establish causation,
scientists can be influenced by their own, non-scientific views of
how burdens of proof should be distributed between plaintiffs and
defendants.
A study of general and specific causation by The National
Academies could be of high value. This institution, through reports
of its expert committees, plays a leading role in the United States
in developing scientific consensuses, and does so through
processes that eliminate, to a high degree, the influence of
individual biases. I suggest the scientific community would greatly
benefit from the kind of guidance The National Academies
provide, and the judicial system will in turn benefit from a clearer
picture of the types of scientific evidence that are appropriate to
bring before juries in matters such as those that are the subject of
this paper.

